UNSPSC 51352416: Ethinyl estradiol/norgestimate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352416 Ethinyl estradiol/norgestimate is a Commodity code representing a specific oral contraceptive combination product that state and local governments procure primarily through pharmacy benefit programs, cooperative purchasing alliances, and health benefit plans serving state employees and beneficiaries. The work involves supply of the branded or generic formulation to state health plans, Medicaid programs, and employee health benefits for distribution through authorized pharmacy networks and wholesalers. State and local issuing bodies soliciting under this code include state health and human services departments managing pharmacy benefit programs, state departments of administration overseeing employee health benefits, and multistate cooperative purchasing alliances aggregating demand across multiple jurisdictions. Recent activity shows movement toward direct-to-manufacturer contracting models and generic multi-source pharmaceutical procurement frameworks that reduce reliance on pharmacy benefit managers and group purchasing organizations.

Recent opportunities span Texas and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, with response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking market intelligence on vendors' ability to contract directly with self-insured employer and state agency health plans and to negotiate net-pricing models without rebates. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon; vendors must supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with pricing weighted at 75 percent of evaluation and contract effectiveness set for July 1, 2026.